ReviewThe CRISPR journal2018
Harnessing "A Billion Years of Experimentation": The Ongoing Exploration and Exploitation of CRISPR-Cas Immune Systems.
Review in The CRISPR journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Type III CRISPR-Cas systems preferentially acquire spacers from early-expressed phage genes in a transcription-dependent manner.Nucleic acids research · 2026Article
- The promise of CRISPR-associated transposons for bacterial functional genomics.Current opinion in microbiology · 2025Review
- Novel adaptive immune systems in pristine Antarctic soils.Scientific reports · 2025Article
- AcrIIIA1 is a protein-RNA anti-CRISPR complex that targets core Cas and accessory nucleases.Nucleic acids research · 2024Article
- Current Updates of CRISPR/Cas System and Anti-CRISPR Proteins: Innovative Applications to Improve the Genome Editing Strategies.International journal of nanomedicine · 2024Review
- Historical Highlight: The Luria-Delbrück Fluctuation Test - A Study of the Nature of Bacterial Mutations Conferring Resistance to Infection by Bacteriophage.Pathogens & immunity · 2024Article
- Insight into the molecular mechanism of the transposon-encoded type I-F CRISPR-Cas system.Journal, genetic engineering & biotechnology · 2023Review
- Disarming of type I-F CRISPR-Cas surveillance complex by anti-CRISPR proteins AcrIF6 and AcrIF9.Scientific reports · 2022Article
- Evolutionary and mechanistic diversity of Type I-F CRISPR-associated transposons.Molecular cell · 2022Article
- Efficient genome editing of an extreme thermophile, Thermus thermophilus, using a thermostable Cas9 variant.Scientific reports · 2021Article
- Approach for in vivo delivery of CRISPR/Cas system: a recent update and future prospect.Cellular and molecular life sciences : CMLS · 2021Review
- Article
- Reproducible Antigen Recognition by the Type I-F CRISPR-Cas System.The CRISPR journal · 2020Article
- Structures and Strategies of Anti-CRISPR-Mediated Immune Suppression.Annual review of microbiology · 2020Review
- PAM recognition by miniature CRISPR-Cas12f nucleases triggers programmable double-stranded DNA target cleavage.Nucleic acids research · 2020Article
- ErCas12a CRISPR-MAD7 for Model Generation in Human Cells, Mice, and Rats.The CRISPR journal · 2020Article
- Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants.Nature reviews. Microbiology · 2020Review
- Genome Mining and Comparative Pathogenomic Analysis of An Endemic Methicillin-ResistantPathogens (Basel, Switzerland) · 2019Article
- Regulation of cyclic oligoadenylate synthesis by theRNA (New York, N.Y.) · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The famed physicist-turned-biologist, Max Delbrück, once remarked that, for physicists, "the field of bacterial viruses is a fine playground for serious children who ask ambitious questions." Early discoveries in that playground helped establish molecular genetics, and half a century later, biologists delving into the same field have ushered in the era of precision genome engineering. The focus has of course shifted-from bacterial viruses and their mechanisms of infection to the bacterial hosts and their mechanisms of immunity-but it is the very same evolutionary arms race that continues to awe and inspire researchers worldwide. In this review, we explore the remarkable diversity of CRISPR-Cas adaptive immune systems, describe the molecular components that mediate nucleic acid targeting, and outline the use of these RNA-guided machines for biotechnology applications. CRISPR-Cas research has yielded far more than just Cas9-based genome-editing tools, and the wide-reaching, innovative impacts of this fascinating biological playground are sure to be felt for years to come.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.